Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine Capsules
Drug: Rivastigmine Patch
Drug: Placebo to Rivastigmine capsules
Drug: Placebo to Rivastigmine patch

First Posted Date: 2011-07-21

Last Posted Date: 2014-08-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 501

Registration Number: NCT01399125

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

Phase 4

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Vildagliptin
Drug: Sitagliptin

First Posted Date: 2011-07-20

Last Posted Date: 2013-02-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 187

Registration Number: NCT01398592

Locations: 🇩🇪
Novartis Investigative Site, Stuttgart, Germany

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)

Phase 3

Completed

Conditions: Visual Impairment
Macular Edema
Branch Retinal Vein Occlusion

Interventions: Other: Dexamethasone Implant
Drug: Ranibizumab
Other: Sham injection

First Posted Date: 2011-07-18

Last Posted Date: 2014-08-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 244

Registration Number: NCT01396057

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)

Phase 3

Completed

Conditions: Central Retinal Vein Occlusion
Visual Impairment
Macular Edema

Interventions: Drug: Dexamethasone implant and sham injections
Drug: Ranibizumab

First Posted Date: 2011-07-18

Last Posted Date: 2016-09-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 243

Registration Number: NCT01396083

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Completed

Conditions: Transfusional Hemosiderosis

Interventions: Drug: deferasirox

First Posted Date: 2011-07-14

Last Posted Date: 2016-02-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT01394029

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

Phase 3

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Imatinib
Drug: Sildenafil
Drug: Bosentan

First Posted Date: 2011-07-12

Last Posted Date: 2021-06-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT01392469

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Phase 3

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Imatinib

First Posted Date: 2011-07-12

Last Posted Date: 2015-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01392495

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Phase 2

Completed

Conditions: Primary Myelofibrosis (MF)
Post-Polycythemia Vera (PV) MF
Post-Essential Thrombocythemia (ET) MF

Interventions: Drug: Ruxolitinib

First Posted Date: 2011-07-12

Last Posted Date: 2019-09-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT01392443

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Secukinumab (75 mg)
Drug: Secukinumab (150 mg)
Drug: Placebo Comparator

First Posted Date: 2011-07-12

Last Posted Date: 2016-02-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 606

Registration Number: NCT01392326

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor

Completed

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Interventions: Other: everolimis

First Posted Date: 2011-07-11

Last Posted Date: 2016-01-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01390519

Locations: 🇳🇴
Novartis Investigative Site, Trondheim, Norway

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy